Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1

In Vivo

Volumn 20, Issue 6 B, 2006, Pages 881-886

  Ripoll, Giselle V ^a   Farina, Hernán G ^a   Yoshiji, Hitoshi ^b   Gomez, Daniel E ^a   Alonso, Daniel F ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

DDAVP; Metastasis; TIMP 1; Transgenic animal; Vasopressin analog

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DATA ANALYSIS; DRUG CYTOTOXICITY; ENHANCER REGION; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; SYSTEMIC CIRCULATION; TRANSGENIC MOUSE; TUMOR CELL;

EID: 33846078868     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders, the first 20 years. Blood 90: 2515-2521, 1997.
2. Gomez DE, Ripoll GV, Giron S and Alouso DF: Desmopressin and other synthetic vasopressin analogues in cancer treatment. Bull Cancer 93: E7-12, 2006.
3. Kaufmann JE and Vischer UM: Cellular mechanisms of the hemostatic effects of demopressin (DDAVP). J Thromb Haemos 1: 6682-689, 2003.
4. North WG: Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol 85: 27S-40S, 2000.
5. Alouso DF, Skilton G, Farias EF, Bal de Kier Joffe E and Gomez DE: Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat 57: 271-275, 1999.
6. Giron S, Tejera AM, Ripoll GV, Gomez DE and Alonso DF: Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surg Oncol 81: 38-44, 2002.
7. Mannello F, Tonti G and Papa S: Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 5: 285-298, 2005.
8. Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP: Tissue inhibitors of metalloproteinases; structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997.
9. De Lorenzo MS, Ripoll GV, Yoshiji H, Yamazaki M, Thorgeirsson UP, Alonso DF and Gomez DE: Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 17: 45-50, 2003.
10. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS and Fukui H: Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32: 1248-1254, 2000.
11. Oksche A, Leder G, Valet S, Platzer M, Hasse K, Geist S, Krause G, Rosenthal A and Rosenthal W: Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity. Mol Endocrinol 16: 799-813, 2002.
12. Gabri MR, Lorenzano Menna P, Scursoni AM, Gomez DE and Alonso DF: Role of tumor-derived granulocyte-macrophage colony-stimulating factor in mice beating a highly invasive and metastatic mammary carcinoma. Pathobiology 67: 180-185, 1999.
13. Alonso DF, Farias EF and Bal de Kier Joffe E: Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Cancer Lett 70: 181-187, 1993.
14. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP and Weinberg RA: The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 37: 1047-1054, 2005.
15. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA and Muschel RJ: Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64: 8613-8619, 2004.
16. Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 4: 519-526, 2006.
17. Kanwar S, Woodman RC, Pooh MC, Murohara T, Lefer AM, Davenpeck KL and Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood 86: 2760-2766, 1995.
18. Wun T, Paglieroni TG and Lachant NA: Desmopressin stimulates the expression of P-selectin on human platelets in vitro. J Lab Clin Med 126: 401-409, 1995.
19. Kaufmann JE, Iezzi M and Vischer UM: Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 1(4): 821-828, 2003.
20. Hirano S: In vitro and in vivo cytotoxic effects of nitric oxide on metastatic cells. Cancer Lett 115: 57-62, 1997.
21. Hunter K: Host genetics influence tumour metastasis. Nat Rev Cancer 6: 141-146, 2006.
22. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF: Inhibition by recombinant human tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48: 5539-5545, 1988.
23. Kruger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT, Orr FW, Ruther U and Khokha R: Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16: 2419-2423, 1998.
24. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler Stevenson WG and Oyasu R: Overexpression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 63: 680-687,1995.
25. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D and Wagner DD: Systemic antithrombotic effects of ADAMTS13. J Exp Med 203: 767-776, 2006.
26. Sadler JE: von Willebrand factor: two sides of a coin. J Thromb Haemost 3: 1702-1709, 2005.
27. Gomez DE, Ripoll GV, Giron S and Alouso DF: Desmopressin and other synthetic vasopressin analogues in cancer treatment. Bull Cancer 93: E7-E12, 2006.